United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 6 minute read Healthcare Industry News Solventum (NYSE: SOLV) stock jumps 5% on $850m Acera Surgical acquisition deal Solventum’s $850M Acera deal aims to reshape wound care strategy. See how synthetic matrices and Restrata could drive long-term growth. bySrinathNovember 20, 2025